SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

July 07, 2011 07:00 ET

Radient Pharmaceuticals' Onko-Sure® Is Proven Effective in Early Detection of Lung Cancer

Research Results From the University of Chile Presented as a Scientific Poster at 14th Annual World Conference on Lung Cancer

TUSTIN, CA--(Marketwire - Jul 7, 2011) - Radient Pharmaceuticals Corporation "the Company" or "RPC" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, announced today that researchers at the University of Chile, CeTeCancer (Center for Cancer Technologies), presented a scientific poster and clinical research findings at the 14th Annual World Conference on Lung Cancer in Amsterdam. The poster included information relevant to the clinical utility of Onko-Sure® DR-70® ("DR-70") in the early detection of lung cancer.

The poster was presented at the session for Prognostic and Predictive Markers. Titled, "Detection of Pre-Invasive and Pre-Neoplasic Lesions Using Biological and Genomic Lung Cancer Biomarkers in a High Risk Chilean Population," the poster's abstract was published in the Journal of Thoracic Oncology Volume (6), S980.

The researchers used RPC's Onko-Sure® test as one of two blood tests in their clinical trial on the early detection of lung cancer. The other blood test used was based on a genomic biomarker using SNPs (single nucleotide polymorphisms). The published poster presented information that supports the sensitivity of Onko-Sure® DR-70® to be 90% for confirmed lung cancer patients. Furthermore, in the cohort of high-risk patients for lung cancer, sputum cytology and the Onko-Sure® DR-70® assay were reliable predictors of the outcome of autofluorescent bronchoscopy (AFB), which is a more invasive and expensive procedure. A high percentage of patients with abnormal sputum cytology and positive Onko-Sure® DR-70® showed suspicious images with autofluorescent bronchoscopy (AFB), and were confirmed later as pre malignant lesions and/or inflammation.

Dr. Marta Adonis of the University of Chile, Principal Investigator and Author of the poster, commented, "Having used DR-70® in past studies, we've seen very high levels of sensitivity and specificity for the early detection of lung cancer and we have successfully published these findings. We hope to continue to use DR-70® as a biomarker in our future studies, as our imperative is to implement early detection technologies in Chile."

Co-Principal Investigator and Co-Author Dr. Lionel Gil of the University of Chile added, "We have found that a high percentage of patients who were positive for DR-70® also showed suspicious lesions when using imaging techniques. These were later confirmed as pre-malignant lesions and/or inflammation. We've concluded that DR-70® is a very useful tool in combination with other tests and imaging techniques in the early detection of lung cancer."

"These independent research results further validate our Onko-Sure® test as a clinically useful tool in the early detection of one of the most fatal cancers. It is our aim to move this test towards commercialization. The ability to detect lung cancer at its earliest stages could make a significant and favorable shift in survival rates," stated Radient Pharmaceuticals Chairman and CEO Douglas MacLellan.

The 14th World Conference on Lung Cancer is taking place in Amsterdam, The Netherlands from July 3rd to July 7th, 2011. This international conference is welcoming more than 7,000 delegates from all over the world. It is one of the largest international gatherings of researchers, clinicians and professionals working in the field of thoracic oncology, with almost 1,900 abstracts and more than 120 oral presentation sessions.

For additional information on Radient Pharmaceuticals Corporation and its products visit: or e-mail For Investor Relations contact Dilek Mir at: or 714-881-0244.

The following table is intended to provide the latest information on RPC's business metrics.

RPC's Business Metrics

Cash on hand: $1.4 million*

*Approximate amount as of July 5, 2011

Shares Outstanding: 174 million*

*Approximate number as of July 5, 2011 and there are 200 million shares fully authorized

Outstanding Warrants & Options: 138.7 million*

*Approximate number as of July 5, 2011

About Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.